Grace Therapeutics News

Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating

Moomoo NewsNov 25 10:33 ET

Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)

TipRanksNov 25 09:59 ET

Acasti Pharma Analyst Ratings

BenzingaSep 26 12:12 ET

Craig-Hallum Maintains Acasti Pharma(ACST.US) With Buy Rating, Announces Target Price $8

Moomoo NewsSep 26 09:32 ET

H.C. Wainwright Maintains Acasti Pharma(ACST.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsSep 26 06:31 ET

Acasti Pharma's GTX-104 Shows Promising Future With Buy Rating From Analyst Oren Livnat

TipRanksSep 26 06:25 ET

Craig-Hallum Maintains Acasti Pharma(ACST.US) With Buy Rating

Moomoo NewsAug 14 09:31 ET

Acasti Pharma Analyst Ratings

BenzingaFeb 7 09:09 ET

Analysts Offer Insights on Healthcare Companies: Acasti Pharma (ACST), Omnicell (OMCL) and MoonLake Immunotherapeutics (MLTX)

TipRanksOct 17, 2023 08:33 ET

Optimistic Outlook for Acasti Pharma's GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage Treatment

TipRanksOct 17, 2023 08:30 ET

Analysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)

TipRanksJul 12, 2023 06:20 ET

EF Hutton Remains a Buy on Acasti Pharma (ACST)

TipRanksFeb 15, 2023 07:35 ET

Acasti Pharma Analyst Ratings

Benzinga Analyst RatingsFeb 15, 2023 07:07 ET

EF Hutton Reiterates Buy on Acasti Pharma, Maintains $2.5 Price Target

Benzinga Real-time NewsFeb 15, 2023 07:05 ET

H.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)

TipRanksDec 29, 2022 06:30 ET

EF Hutton Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.5

Benzinga Real-time NewsDec 19, 2022 07:12 ET

Acasti Pharma Analyst Ratings

Benzinga Analyst RatingsDec 19, 2022 07:12 ET

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Acasti Pharma (ACST) and Avidity Biosciences (RNA)

TipRanksDec 15, 2022 09:50 ET

HC Wainwright & Co. Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.4

Benzinga Real-time NewsDec 15, 2022 07:44 ET

Acasti Pharma Analyst Ratings

Benzinga Analyst RatingsDec 15, 2022 07:43 ET